

SEED STAGE INVESTMENT OPPORTUNITY

Stimulating change.

Evren is advancing the treatment of PTSD and other neuropsychological disorders through bioelectronic medicine. Our flagship device, the Phoenix™, delivers Vagal Nerve Stimulation (taVNS) in a discreet earbud design. We aim to be the first medical device for the treatment of PTSD and the first wearable taVNS device in a consumer wireless earbud design.

THE PTSD MARKET

8.6 Mil

Suffering from PTSD in the United States

66%

Still looking for relief after treatment

\$7,000/year

Average treatment cost and lost productivity

\$9 Bil

Annual US Market

INTRODUCING THE PHOENIX™



- 1st Will be 1st FDA approved device for PTSD
- Non-invasive, non-pharmacological treatment
- No significant adverse side effects

5

Phoenix™ Product Features

- Treats the root cause of PTSD, not just symptom level relief
- Restores the body's natural parasympathetic balance
- Multiple modes to meet unique needs of each PTSD patient

Phoenix™ Software Ecosystem



Delivering Personalized Therapy



HOW VAGAL NERVE STIMULATION WORKS

taVNS, or transcutaneous stimulation of the auricular branch of the vagus nerve, is ideal for multiple reasons. The first is that it only targets afferent fibers, which means electrical signals are sent directly to the brain centers involved in PTSD. taVNS also allows for non-invasive treatment of PTSD, has been proven as effective as implantable VNS but with no significant adverse side effects, and provides a comfortable and discreet ear placement.

Proven Reduction of PTSD Symptoms

- Hypervigilance
- Asocial behavior
- Anxiety
- Depression

Scalable To Multiple Disease States & Markets

- Mild cognitive impairment
- Depression & Anxiety
- Insomnia
- Pain & Addiction

- ADHD
- Rehabilitation from stroke & spinal injury
- Enhanced learning

SEEKING \$3 MILLION SEED INVESTMENT



SG&A PRODUCT DEVELOPMENT **QUALITY & REGULATORY CLINICAL TRIAL**

PHASE 1—Derisk & Define*

- Applied for Breakthrough Device Designation with FDA
- Patient mapping & reimbursement landscape
- Product feature definition & early prototyping
- *Convertible note round of \$500,000 closed 4Q2019.

\$3 MILLION PREFERRED STOCK

PHASE 2—Perfect & Pilot

- Completion of clinical device
- Earbud Industrial Design
- Closed loop PTSD Pilot

PHASE 3—Test & Trial

- V&V testing

IFU & product labeling FDA clinical trial & DeNovo submission

Go-To-Market Strategy

DeNovo FDA submission

Currently speaking with FDA about Breakthrough **Device Designation**

Unit device margins

• \$2,200 for initial purchase


 \$200 recurring revenue on 6-mo replacement ear fittings

Dual Sales Streams

• Clinician – Independent sales reps calling on PTSD treatment centers and behavioral health group practices

· Patient - Digital Direct-to-Consumer sales boosted by targeted marketing to PTSD Symptom Tracker App

Future revenue streams through CMS coding and large self-employer contracts





MANAGEMENT



WEAVER GAINES, CEO

- Founder & CEO of multiple biotech start-ups
- President & CEO of OB Medical, successful sale to Philips
- . B.A. in Philosophy, **Dartmouth College**
- J.D., University of Virginia School of Law



BLYTHE KAROW, PRESIDENT & COO

- Experience developing & launching neuromodulation devices
- Multiple roles in Management & Strategic consulting
- B.S. in Biomedical Engineering, Johns Hopkins University
- M.B.A., University of Virginia **Darden School of Business**



NEIL EULIANO, CTO

- · Long history managing medical development teams
- Over 40 US patents & 6 FDA clearances
- · Ph.D. in Signal Processing & Electrical Eng, M.S.E.E. in Electrical Eng, & B.S.E. in Computer Science, University of Florida

OUR PARTNERS



Focusing on user-centric design, SlideWave develops software that your users will love.



Working at the intersections of science, technology, and business to build complex medical technology and healthcare products for clients worldwide.